Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.

Journal of registry management - 1 Jan 2016

Styles Timothy, Wu Manxia, Wilson Reda, Babcock Frances, Butterworth David, West Dee W, Richardson Lisa C

Abstract excerpt

INTRODUCTION: National and international hematology/oncology practice guidelines recommend testing for the BCR-ABL mutation for definitive diagnosis of chronic myeloid leukemia (CML) to allow for appropriate treatment with a tyrosine kinase inhibitor (TKI). The purpose of our study was to describe population-based testing and treatment practice characteristics for patients diagnosed with CML. METHODS: We analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to BCR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 28121314
PMCID: PMC5291176

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.PMID 28121314Read ↗

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.Semantic proximity Read ↗

Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results databaseSemantic proximity Read ↗

Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Semantic proximity Read ↗

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.Semantic proximity Read ↗

Impact of a Guaranteed Access Program to Imatinib on the Survival of Patients with Chronic Myeloid LeukemiaSemantic proximity Read ↗

Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateSemantic proximity Read ↗

Development of an Integrated Assay for Detection of BCR-ABL RNASemantic proximity Read ↗

BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.Semantic proximity Read ↗

Analysis of the Gap in PCR Monitoring Availability for Patients with Chronic Myeloid Leukemia in 60 Low- and Middle-Income CountriesSemantic proximity Read ↗

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.Semantic proximity Read ↗

Impact of race on outcomes in intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.